Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats

Executive Summary

• Innocan Pharma announced the publication of a peer‑reviewed study demonstrating that repeated sub‑cutaneous injections of its synthetic liposomal cannabidiol (LPT‑CBD) in two goats provided sustained plasma CBD levels, excellent tolerability, no liver enzyme elevations, and marked pain relief over a 10‑month period.
• The findings support the company’s claim that LPT‑CBD can be administered every six weeks as a non‑opioid chronic pain therapy with a favorable long‑term safety profile, bolstering its pipeline toward human trials.
• Management highlighted the translational relevance of the data for future clinical development and potential market entry of LPT‑CBD in chronic pain indications.

Key Details

• Study Design: Two goats with chronic painful conditions received 5 mg/kg sub‑cutaneous LPT‑CBD injections every six weeks (total of 7 injections per animal) over ten months.
• Pharmacokinetics: Repeated dosing maintained steady CBD plasma concentrations consistent with a slow‑release profile.
• Safety/Tolerability: No adverse events recorded; liver enzymes remained unchanged, contrasting with reported elevations from repeated oral CBD use in humans.
• Efficacy Outcomes: Caregiver‑reported quality‑of‑life scores indicated sustained pain relief, improved mobility, and enhanced overall wellbeing throughout the study period.
• Publication: Results published in Frontiers in Pharmacology (doi:10.3389/fphar.2025.1689226).
• Management Comments:
• Prof. Chezy Barenholz (Head of Advisory Board) emphasized the “sustained beneficial effects” and translational promise for chronic conditions.
• Dr. Eyal Kalo (VP R&D) noted the favorable long‑term safety profile, particularly the lack of liver enzyme elevation.
• Forward‑Looking Statements: Company plans to pursue human trials of LPT‑CBD; timelines subject to regulatory approvals and other risks disclosed in the release.

Notable Quotes

“The findings of this study highlight the sustained beneficial effects of LPT‑CBD observed over 10 months of repeated administration,” – Prof. Chezy Barenholz, Head of the Advisory Board.

“This study demonstrates that repeated LPT‑CBD administration… does not elevate liver enzymes, supporting a favorable long‑term safety profile,” – Dr. Eyal Kalo, Vice President of Research and Development.